Biotech Startups

SentreHeart appears to now redirect to AtriCure, Inc., a medical device company. Its content references products such as the cryoXT probe for reducing residual limb pain related to amputation.

3 investors

Seraxis is a regenerative medicine company developing a replacement cell therapy for insulin-dependent (Type 1) diabetes, using engineered islet cells to replace those missing in patients. It pursues scientific collaborations and licensing partnerships around its cell therapy technologies.

3 investors

Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome. The company pioneered the development and FDA approval of VOWST, an oral live biotherapeutic.

3 investors

ShapeTX develops programmable RNA medicines by combining artificial intelligence with RNA technology to address genetic causes of disease.

3 investors

The company develops diagnostics and biological sample collection devices, including a rapid sickle-cell test, supporting infectious disease detection and genomic, metabolomic, and microbiome research. It serves healthcare, public health, and scientific research markets.

3 investors

Shift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis. The company works in the aging and longevity biotech field, having discovered novel aging targets linked to disease states.

3 investors

Sight develops immune signatures by analyzing live immune cells using AI to generate clinical insights. The company applies proprietary data and machine learning to immune cell analysis for diagnostic and clinical applications.

3 investors

Sigma Genetics is a biotechnology company developing devices that use magnetic fields to deliver DNA, RNA, and other charged molecules into cells as an alternative to conventional electroporation. The platform technology targets applications including cell therapies, cancer drug delivery, DNA vaccines, biopharma manufacturing, and cosmetics.

3 investors

Silvec develops RNA-based therapies to protect trees, vines, and bushes from viral, bacterial, and fungal diseases without modifying the host genome. Its treatments use a proprietary type of RNA and are aimed at agricultural and horticultural crops such as citrus, olive, cacao, and banana trees.

3 investors

Simcha is a biotechnology company developing new cancer medicines based on immune biology research. It focuses on translating discoveries in immune biology into oncology drugs for patients with cancer.

3 investors

Simergent develops medical device systems for regulated healthcare markets, with expertise in peritoneal dialysis and infusion pump technologies. The company is led by engineers with FDA clearance experience and clinical advisory from nephrologists.

3 investors

Singleron Biotechnologies develops single-cell and single-nucleus sequencing kits and solutions for transcriptome analysis of biological samples. The company serves research institutions and laboratories conducting genomics and molecular biology research.

3 investors

SiriusXT develops the SXT-100 soft X-ray microscope, a laboratory-based imaging system that produces nanometer-resolution 3D images of fully hydrated intact cells. The instrument serves research institutions and biotech companies studying subcellular structures and cellular biology.

3 investors

Sironax is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases. Its research targets conditions affecting longevity, those requiring supportive care, and certain rare diseases.

3 investors

SiteRx works to make clinical research more accessible by improving transparency and diversity in clinical trials, connecting patients with research opportunities for their medical conditions. The company focuses on bringing treatments to market more efficiently, with a stated interest in Alzheimer's disease research.

3 investors

Sixfold Bioscience develops patented drug delivery systems for RNA therapeutics, including siRNAs for gene silencing and mRNAs for gene expression. The company works on commercialising these delivery technologies in the gene therapy and nanomedicine space.

3 investors

Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling. The company translates bone biology research into therapies designed to protect and rebuild bone.

3 investors

Sleuth provides evidence-backed answers for biopharma decision-making, built on a knowledge graph that maps over a billion relationships across biology, clinical evidence, competitive dynamics, and deal history. It ingests data from hundreds of structured and unstructured sources—including sell-side research, patents, SEC filings, and Chinese biotech pipelines—with full traceability from each output back to its source.

3 investors

SOLA Biosciences is a preclinical-stage biopharmaceutical company developing gene therapies for neurodegenerative diseases like ALS, Huntington's Disease, and Alzheimer's Disease by targeting misfolded proteins. The company uses its proprietary JUMP70 platform to restore protein homeostasis and deliver disease-modifying treatments.

3 investors

Solarea Bio develops plant-sourced living synbiotics (probiotics plus prebiotics) as medical foods targeting inflammatory conditions, starting with bone loss in women with osteopenia. Its clinically tested products aim to address underserved conditions such as osteopenia and rheumatoid arthritis.

3 investors

Solid Biosciences is a precision genetic medicine company developing a pipeline of gene therapy candidates for rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy, Friedreich's ataxia, CPVT, and TNNT2-mediated dilated cardiomyopathy. It also develops genetic regulator libraries and delivery platform technologies intended to improve gene therapy delivery.

3 investors

Solid IO develops a tumor-on-chip platform using organ-on-chip technology and AI to model patient-specific tumor microenvironments for oncology and immunotherapy research. The platform enables pharmaceutical companies, biotech firms, and cancer clinics to predict treatment responses, accelerate drug development, and support precision medicine in cancer care.

3 investors

Solve Therapeutics is a clinical-stage oncology biotech developing antibody-drug conjugates (ADCs) and radiopharmaceuticals for solid tumors, built around its CloakLink hydrophilic cleavable linker platform and an integrated diagnostic for patient selection. The company has two lead programs in Phase 1 clinical development.

3 investors

Sonovascular is developing an interventional treatment for venous thromboembolism (VTE) that uses microbubble-mediated cavitation, delivered as a cath lab-based procedure without requiring ICU treatment. The company operates in the cardiovascular medical device space.

3 investors